Leadership

Management team

Jesper Boysen - E-MBA

Chief Executive Officer
and Board Member

Jesper has been CEO of Nanovi since September 2017. He has extensive strategic, commercial and business development experience from previous senior management positions in the MedTech industry. He has been EVP at Mediq BV, CEO at Mediq Danmark, CEO at SDC DanDisc A/S and Nordic general manager at Mølnlycke Health Care. Jesper is founder and CEO of Micocou Holding. He holds an E-MBA in Business Administration and Graduate Diplomas in Finance and Marketing.

Hanne Leth Hillman - MBA

Chief Financial Officer

Hanne joined Nanovi as CFO in May 2017. She has a broad span of competences in the fields of finance, capital and investor market relations and corporate communication. She has +10 years of experience from previous senior management positions in publicly listed life science companies and +10 years of experience from life science investment banking, corporate finance and equity research. Hanne holds a Master of Science in Business Administration and International Finance.

Sten Naae Hornsleth - MSc, PhD

Director, Sales and Marketing

Sten joined Nanovi in January 2019. He has +20 years of experience from the medical device industry, which includes +14 years in a position as Managing Director of the Scandinavian subsidiary of Varian Medical Systems, a world leading supplier of specialized radiotherapy equipment. Previously, Sten has held sales and project management positions in Siemens Medical Solutions in Denmark and product management positions in Siemens Medical Solutions in Norway/Germany in the area of radiology and IT. Sten holds a Master of Science and a PhD. in Electronic Engineering.

Hsiao-Qing Chow - MSc

Director, Regulatory Affairs

Chow joined Nanovi in 2016 as Senior Regulatory Affairs Manager and was appointed to Director of Regulatory Affairs in June 2018 with responsibility for regulatory affairs, quality management system, design control and risk management. Chow has +7 years of experience from previous positions in the medical device industry, including several years with Coloplast. Chow holds a Master of Science in Pharmacy.

Michael Wrang Mortensen - MSc, PhD

Director, Development & Supply

Michael joined Nanovi in July 2018. He has +10 years of previous experience from the MedTech industry, including several years with Ferrosan Medical Devices A/S collaborating closely with Ethicon Biosurgery Inc., Johnson & Johnson. He has held management and leadership positions in global R&D teams as well as in commercial development and operational projects in both small and international organizations. Michael holds a Master of Science in Engineering from the Danish Technical University and a PhD degree in Chemistry.

Jolanta Klovaite - MD, PhD

Director, Clinical Affairs

Jolanta joined Nanovi in March 2019. She is a medical doctor with 6 years of experience from broad clinical practice. Previous to joining Nanovi, Jolanta has worked 6 years in the pharmaceutical industry, including positions as investigator, safety advisor, and international medical manager with Novo Nordisk A/S and H. Lundbeck A/S. Jolanta holds a University degree as a Medical Doctor from Kaunas University, Lithuania and is authorized as physician in Denmark. She is also certified as Medical Specialist in Clinical Biochemistry by the Danish National Board of Health and holds a PhD degree in Health Sciences from Copenhagen University.

Board of Directors

Simon Hesse Hoffmann

Chairman

Simon joined the Board in May 2018 and became Chairman of the Board in December 2018. He is Director of JHO Holding ApS and has previously held financial positions in several publicly listed Danish companies, including a position as Head of Group Treasury in DFDS A/S. His experience spans financial management, governance and reporting as well as budgeting and corporate funding. Simon is member of the board in HolmeTex ApS and WireOnAir A/S, and he is Chairman of the Board in the SMIL Foundation (SMILfonden) . Simon holds a Master of Science in Finance and International Business.

Jesper Boysen

Jesper was previously EVP at Mediq BV, CEO at Mediq Danmark, CEO at SDC DanDisc A/S and Nordic general manager at Mølnlycke Health Care. Jesper is founder and CEO of Micocou Holding. He holds an E-MBA in Business Administration and Graduate Diplomas in Finance and Marketing.

Ole Kring

Ole joined the Board in December 2018. He is Investment Director in Vækstfonden’s Life Science team and represents Vækstfonden on the Board of Directors. Ole has extensive management, commercial and operational experience. He is the founder of Scandinavian Micro Biodevices, where he was CEO for 12 years, including after the company was acquired by Zoetis Inc. in 2016. Ole holds a Master of Science in Economy & Business Administration.

Flemming Thorup

Flemming has several board positions including of 3Shape Group. President & CEO of 3Shape Group from its inception in 2001 to 2017. Prior to this, he held senior executive positions at Amersham/ Nycomed and Novo Nordisk. Flemming holds a Master of Science in Economics and an MBA in Management.

Gordon McVie

Gordon is an international authority on the treatment and research of cancer. He is the co-founding editor of ecancermedicalscience, an open-access cancer journal. He is Chair of Proton Partners International, Visiting professor, MD at Kings College, London and Senior clinical advisor, Italian Laboratory for Molecular Oncology. Previously CEO of Cancer Research UK.

Thomas L. Andresen

Thomas is the founder of Nanovi. He is Master of Science, Ph.D and Professor at Danish Technological University (DTU), Healthtech, where he also leads the “Colloids and Biological Interfaces” group. Thomas has more than 20 years of research and development experience in the fields of organic chemistry, biophysics, advanced materials engineering, and cancer biology and is an author on more than 100 research or review articles and multiple patent applications. Thomas is Chief Scientific Officer and a co-founder at Torque Therapeutics Inc, a Boston, US based biopharmaceutical company, developing cell therapies for cancer.